Tags

Type your tag names separated by a space and hit enter

Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
Anticancer Res. 2003 Mar-Apr; 23(2A):1115-8.AR

Abstract

BACKGROUND

CA-125 is the most important tumor marker in epithelial ovarian cancer. Due to its low specificity, a combination with CASA may improve the clinical discrimination between benign and malignant adnexal masses.

MATERIALS AND METHODS

In a prospective study CA-125 and CASA were analyzed in blood specimens of 153 patients, including 29 ovarian cancer.

RESULTS

The median levels of both markers were significantly higher in ovarian cancer than in benign diseases. The sensitivity of CA-125 was 90%, while the specificity was 79%. PPV and NPV were 50% and 97%. In comparison, the sensitivity of CASA was lower (38%), while the specificity was slightly higher (86%). PPV and NPV were 39% and 86%. When both markers were used together, the specificity could be increased to 96% but the sensitivity remained at only 38%. The PPV and NPV was 69% and 87%.

CONCLUSION

The combination of CA-125 and CASA can improve the detection of patients with suspected ovarian cancer.

Authors+Show Affiliations

Charité, Department of Obstetrics and Gynaecology, Humboldt University, Augustenburger Platz 1, D-13353 Berlin, Germany. sehouli@aol.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

12820357

Citation

Sehouli, Jalid, et al. "Preoperative Determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the Discrimination Between Benign and Malignant Pelvic Tumor Mass: a Prospective Study." Anticancer Research, vol. 23, no. 2A, 2003, pp. 1115-8.
Sehouli J, Akdogan Z, Heinze T, et al. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res. 2003;23(2A):1115-8.
Sehouli, J., Akdogan, Z., Heinze, T., Könsgen, D., Stengel, D., Mustea, A., & Lichtenegger, W. (2003). Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Research, 23(2A), 1115-8.
Sehouli J, et al. Preoperative Determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the Discrimination Between Benign and Malignant Pelvic Tumor Mass: a Prospective Study. Anticancer Res. 2003 Mar-Apr;23(2A):1115-8. PubMed PMID: 12820357.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. AU - Sehouli,Jalid, AU - Akdogan,Zera, AU - Heinze,Thomas, AU - Könsgen,Dominique, AU - Stengel,Dirk, AU - Mustea,Alexander, AU - Lichtenegger,Werner, PY - 2003/6/25/pubmed PY - 2003/8/2/medline PY - 2003/6/25/entrez SP - 1115 EP - 8 JF - Anticancer research JO - Anticancer Res VL - 23 IS - 2A N2 - BACKGROUND: CA-125 is the most important tumor marker in epithelial ovarian cancer. Due to its low specificity, a combination with CASA may improve the clinical discrimination between benign and malignant adnexal masses. MATERIALS AND METHODS: In a prospective study CA-125 and CASA were analyzed in blood specimens of 153 patients, including 29 ovarian cancer. RESULTS: The median levels of both markers were significantly higher in ovarian cancer than in benign diseases. The sensitivity of CA-125 was 90%, while the specificity was 79%. PPV and NPV were 50% and 97%. In comparison, the sensitivity of CASA was lower (38%), while the specificity was slightly higher (86%). PPV and NPV were 39% and 86%. When both markers were used together, the specificity could be increased to 96% but the sensitivity remained at only 38%. The PPV and NPV was 69% and 87%. CONCLUSION: The combination of CA-125 and CASA can improve the detection of patients with suspected ovarian cancer. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/12820357/Preoperative_determination_of_CASA__Cancer_Associated_Serum_Antigen__and_CA_125_for_the_discrimination_between_benign_and_malignant_pelvic_tumor_mass:_a_prospective_study_ L2 - https://antibodies.cancer.gov/detail/CPTC-MUC16-1 DB - PRIME DP - Unbound Medicine ER -